Pramipexole - CAS 104632-26-0
Catalog number: 104632-26-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C10H17N3S
Molecular Weight:
211.33
COA:
Inquire
Targets:
Dopamine Receptor
Description:
Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.
Purity:
>98%
Synonyms:
SND 919; SND919; SND-919
MSDS:
Inquire
InChIKey:
FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI:
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
Canonical SMILES:
CCCNC1CCC2=C(C1)SC(=N2)N
1.Opposing Effects of Dopamine D1- and D2-Like Agonists on Intracranial Self-Stimulation in Male Rats.
Lazenka MF, Legakis LP, Negus SS. Exp Clin Psychopharmacol. 2016 Mar 17. [Epub ahead of print]
Dopamine acts through dopamine Type I receptors (comprising D1 and D5 subtypes) and dopamine Type II receptors (comprising D2, D3, and D4 subtypes). Intracranial self-stimulation (ICSS) is 1 experimental procedure that can be used to evaluate abuse-related effects of drugs targeting dopamine receptors. This study evaluated effects of dopamine receptor ligands on ICSS in rats using experimental procedures that have been used previously to examine abused indirect dopamine agonists such as cocaine and amphetamine. Male Sprague-Dawley rats responded under a fixed-ratio 1 schedule for electrical stimulation of the medial forebrain bundle, and frequency of stimulation varied from 56-158 Hz in 0.05 log increments during each experimental session. Drug potency and time course were determined for the D1 ligands A77636, SKF82958, SKF38393, fenoldopam, and SCH39166 and the D2/3 ligands sumanirole, apomorphine, quinpirole, PD128907, pramipexole, aripiprazole, eticlopride, and PG01037.
2.Distinct Effects of Chronic Dopaminergic Stimulation on Hippocampal Neurogenesis and Striatal Doublecortin Expression in Adult Mice.
Salvi R1, Steigleder T2, Schlachetzki JC3, Waldmann E4, Schwab S5, Winner B6, Winkler J1, Kohl Z1. Front Neurosci. 2016 Mar 11;10:77. doi: 10.3389/fnins.2016.00077. eCollection 2016.
While adult neurogenesis is considered to be restricted to the hippocampal dentate gyrus (DG) and the subventricular zone (SVZ), recent studies in humans and rodents provide evidence for newly generated neurons in regions generally considered as non-neurogenic, e.g., the striatum. Stimulating dopaminergic neurotransmission has the potential to enhance adult neurogenesis in the SVZ and the DG most likely via D2/D3 dopamine (DA) receptors. Here, we investigated the effect of two distinct preferential D2/D3 DA agonists, Pramipexole (PPX), and Ropinirole (ROP), on adult neurogenesis in the hippocampus and striatum of adult naïve mice. To determine newly generated cells in the DG incorporating 5-bromo-2'-deoxyuridine (BrdU) a proliferation paradigm was performed in which two BrdU injections (100 mg/kg) were applied intraperitoneally within 12 h after a 14-days-DA agonist treatment. Interestingly, PPX, but not ROP significantly enhanced the proliferation in the DG by 42% compared to phosphate buffered saline (PBS)-injected control mice.
3.The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasm
McCormick PN1, Fletcher PJ2, Wilson VS3, Remington GJ4. Life Sci. 2016 Mar 11. pii: S0024-3205(16)30165-5. doi: 10.1016/j.lfs.2016.03.017. [Epub ahead of print]
Pramipexole is a dopaminergic agonist used in Parkinson's disease treatment. It is thought to exert its therapeutic and side effects through actions on dopamine D3 receptors. In a recent study, we found that at doses occupying D3 but not D2 receptors pramipexole reduced locomotion and operant responding for primary and conditioned reinforcement. These effects, however, were not blocked by a D3 receptor antagonist and were present in D3 knockout mice, suggesting non-D3 receptor mechanisms. Among the next highest affinity binding sites of pramipexole are adrenergic α2 receptors. Here we explored α2 receptor involvement in the behavioural effects of pramipexole. We found that the α2 antagonist atipamezole, which was itself behaviourally silent, counteracted pramipexole's reduction of locomotion, but not operant responding for water or a conditioned reinforcer. The resulting behavioural profile was similar to that of a higher dose of pramipexole, leading to the hypothesize that atipamezole mediates its behavioural effects by increasing pramipexole effective dose.
4.RBD and Neurodegenerative Diseases.
Jiang H1, Huang J1, Shen Y1, Guo S1, Wang L1, Han C1, Liu L1, Ma K1, Xia Y1, Li J1, Xu X1, Xiong N1, Wang T2. Mol Neurobiol. 2016 Mar 31. [Epub ahead of print]
Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder characterized by enacting one's dreams during the REM sleep, with most of the dreams being violent or aggressive, so that patients often come to see the doctor complaining hurting themselves or bed partners during sleep. Prevalence of RBD, based on population, is 0.38-2.01 %, but much higher in patients with neurodegenerative diseases, especially synucleinopathies. RBD may herald the emergence of synucleinopathies by decades, such that it may be used as an effective early marker of neurodegenerative diseases. Pharmaceutical treatment of RBD includes clonazepam, melatonin, pramipexole, and some newly reported medications. In this review, we summarized the clinical and PSG features of RBD, the pathophysiology and the therapy of it, focusing on the correlation between neurodegenerative diseases and RBD, in order to emphasize the significance of RBD as an early marker of neurodegenerative diseases.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 170857-36-0 Sonepiprazole hydrochloride

Sonepiprazole hydrochloride
(CAS: 170857-36-0)

Sonepiprazole hydrochloride is a selective dopamine D4 antagonist and displays low affinity for other dopamine receptors, and noradrenalin, serotonin and histam...

CAS 108179-91-5 SKF 83566 hydrobromide

SKF 83566 hydrobromide
(CAS: 108179-91-5)

SKF 83566 hydrobromide is a potent and selective dopamine D1-like receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 μM for D2). SKF 83566 is also reported to be a...

CAS 62421-56-1 TL 99 hydrobromide

TL 99 hydrobromide
(CAS: 62421-56-1)

TL 99 hydrobromide is a putative dopamine autoreceptor agonist.

CAS 28094-15-7 Oxidopamine hydrochloride

Oxidopamine hydrochloride
(CAS: 28094-15-7)

Oxidopamine hydrochloride, also called as 6-OHDA, is a selective catecholaminergic neurotoxin that selectively destroy dopaminergic and noradrenergic neurons in...

CAS 91374-20-8 Ropinirole HCl

Ropinirole HCl
(CAS: 91374-20-8)

Ropinirole a selective D-2 agonist with Ki of 29 nM.

CAS 182210-74-8 (S)-5-Hydroxy-DPAT hydrobromide

(S)-5-Hydroxy-DPAT hydrobromide
(CAS: 182210-74-8)

A potent and selective dopamine (DA) D2 receptor agonist.

CAS 67287-95-0 SKF 83959 hydrobromide

SKF 83959 hydrobromide
(CAS: 67287-95-0)

SKF 83959 hydrobromide is a dopamine D1-like receptor partial agonist (Ki = 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors, respectively), exhib...

CAS 300561-58-4 SKF 77434 hydrobromide

SKF 77434 hydrobromide
(CAS: 300561-58-4)

SKF 77434 hydrobromide is a selective dopamine D1-like receptor partial agonist (IC50 = 19.7 and 2425 nM for binding to D1-like and D2-like receptors, respectiv...

Chemical Structure

CAS 104632-26-0 Pramipexole

Quick Inquiry

Verification code

Featured Items